Objective: Radiofrequency ablation (RFA) has gained recognition as a minimally invasive alternative to surgery for managing symptomatic benign thyroid nodules. However, predicting RFA efficacy remains challenging, especially in identifying patients who may require multiple treatment sessions. The aim of the present study is to identify predictors of suboptimal volume reduction (SVR), defined as failure to achieve a volume reduction greater than 5% between 6 and 12 months after procedure and persistence of symptoms. Methods: A retrospective single-center analysis of consecutive patients who underwent a single RFA procedure for benign thyroid at Verona University Hospital between 2020 and 2023 was conducted. Clinical data, including nodule volume and compressive symptoms, were collected preoperatively and at 1, 6, and 12 months post-RFA. Regression analysis was performed to identify predictors of SVR and persistence of symptoms. Results: A total of 50 patients were included. Baseline nodule volume, higher ACR-TIRADS score, and higher body mass index (BMI) were identified as independent predictors of SVR (p < 0.05). At 12 months, 18.4% of patients reported persistent compressive symptoms; however, no significant predictors of symptom persistence were identified. Conclusions: RFA is effective in reducing benign thyroid nodule volume, with a minority of patients experiencing persistent symptoms. Baseline nodule volume, ultrasonographic characteristics, and BMI significantly influence RFA outcomes, suggesting the need for additional procedures. Further studies are required to identify predictors of treatment response, enhancing patient selection and optimizing therapeutic efficacy.

Introduction: Papillary thyroid carcinoma (PTC) frequently involves cervical lymph nodes. Lateral nodal involvement without central compartment disease (Skip Metastasis, SM) poses diagnostic and staging challenges. We aimed to characterize clinicopathological features of SM in a large multicenter European cohort comparing SM+ (lateral only) and SM- (central + lateral) disease. Materials and methods: We conducted a retrospective study across four high-volume European centers (01/2020-12/2022). Adults with histologically proven PTC, confirmed lateral cervical metastases, and both central (level VI) and lateral (levels II–IV) dissections were included. Additional subanalyses among pT1a and cases with >2 central nodes retrieved were employed to control for confounders. Results: Among 283 patients, 48 (17.0%) were SM +. SM+ patients were older (47 vs 39 years, p=0.006) and had smaller primaries (12 vs 16 mm, p=0.008), fewer microfoci (2 vs 3, p=0.013), fewer lateral nodes retrieved (22 vs 25, p=0.004), fewer positive nodes (2 vs 4, p<0.001), and smaller largest metastatic node (14.5 vs 18.5 mm, p=0.010). Follicular variant was prevalent in SM+ (18.8% vs 4.3%; p=0.001). Features of aggressiveness were less frequent in SM+: multifocality (62.5% vs 74.9%, p=0.016), bilaterality (37.5% vs 52.8%, p=0.024), microscopic ETE (33.3% vs 52.3%, p=0.016), LVI (14.6% vs 47.7%, p2 central nodes; n=252. pT1a tumors n=73). In multivariable analysis, central nodal yield (OR 1.13, p=0.003) and LVI (OR 6.5, p=0.005) were associated with SM-, whereas follicular variant was inversely associated (OR 0.24, p=0.028). Conclusion: SM were not uncommon and associated with a less aggressive clinicopathologic profile and increased proportion of follicular variant. While limited central nodal yield may pose false positive risks, key associations persisted after adjustment. Prospective studies are warranted to refine risk stratification and surgical planning.

Background: The ERAS (Enhanced Recovery After Surgery) protocol is a multidisciplinary perioperative care pathway aimed at improving postoperative recovery. Few studies have investigated their effectiveness in thyroid surgery. The aim of this study was to evaluate the potential clinical benefits of a structured ERAS protocol applied to thyroid surgery in a tertiary referral center. Methods: We conducted a single-center retrospective study on consecutive series of patients undergoing thyroid surgery for benign or malignant disease before (January 2018–December 2022) and after (May 2024–July 2024) the introduction of the ERAS protocol. A propensity score matching (PSM) analysis was used, matching the groups for age, gender, BMI and type of surgery. Results: After PSM, 64 matched patient pairs were analyzed. ERAS patients showed a significant reduction in length of hospital stay (p < 0.001), postoperative nausea and vomiting (3.1% vs. 12.5%, p = 0.04), and pain with an NRS > 5 12 h after surgery (9.4% vs. 26.6%, p = 0.01). Patients in the ERAS group showed significantly higher calcium levels at 6 h (9.09 vs. 8.7 mg/dL, p < 0.001) and 24 h (8.8 vs. 8.6 mg/dL, p = 0.008) postoperatively, with a reduction in the need for intravenous calcium therapy (0% vs. 12.5%, p = 0.003). Conclusions: This study showed significant clinical benefits and reduced length of stay were achieved in thyroid surgery patients after the implementation of a structured ERAS protocol with potential implications for healthcare cost reduction.